The reporting of blinding in physical medicine and rehabilitation randomized controlled trials: A systematic review

Journal of Rehabilitation Medicine

Volumn 45, Issue 1, 2013, Pages 6-13

  Villamar, Mauricio F ^a,b   Contreras, Vanessa Suárez ^a   Kuntz, Richard E ^c   Fregni, Felipe ^a  

^a and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR   (Ecuador)

^c MEDTRONIC INC   (United States)

Author keywords

Blinding; Clinical research; Physical medicine; Randomized controlled trials as topic; Rehabilitation

Indexed keywords

EPIDEMIOLOGY; HUMAN; MEDICAL RESEARCH; PRACTICE GUIDELINE; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHABILITATION MEDICINE; REVIEW; STANDARD; STANDARDS;

BIOMEDICAL RESEARCH; EPIDEMIOLOGIC RESEARCH DESIGN; GUIDELINE ADHERENCE; HUMANS; PHYSICAL AND REHABILITATION MEDICINE; PUBLISHING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84872510740     PISSN: 16501977     EISSN: None     Source Type: Journal    
DOI: 10.2340/16501977-1071     Document Type: Review

References (37)

1. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010; 63: E1-e37.
2. Schulz KF, Chalmers I, Altman DG. The landscape and lexicon of blinding in randomized trials. Ann Intern Med 2002; 136: 254-259.
3. Hrobjartsson A, Boutron I. Blinding in randomized clinical trials: Imposed impartiality. Clin Pharmacol Ther 2011; 90: 732-736.
4. Polit DF, Gillespie BM, Griffin R. Deliberate ignorance: A systematic review of blinding in nursing clinical trials. Nurs Res 2011; 60: 9-16.
5. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 1994; 44: 16-20.
6. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
7. Nuesch E, Reichenbach S, Trelle S, Rutjes AW, Liewald K, Sterchi R, et al. The importance of allocation concealment and patient blinding in osteoarthritis trials: A meta-epidemiologic study. Arthritis Rheum 2009; 61: 1633-1641.
8. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Metaepidemiological study. BMJ 2008; 336: 601-605.
9. Boutron I, Tubach F, Giraudeau B, Ravaud P. Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials. J Clin Epidemiol 2004; 57: 543-550.
10. Fregni F, Imamura M, Chien HF, Lew HL, Boggio P, Kaptchuk TJ, et al. Challenges and recommendations for placebo controls in randomized trials in physical and rehabilitation medicine: A report of the international placebo symposium working group. Am J Phys Med Rehabil 2010; 89: 160-172.
11. Deyo RA, Walsh NE, Schoenfeld LS, Ramamurthy S. Can trials of physical treatments be blinded? The example of transcutaneous electrical nerve stimulation for chronic pain. Am J Phys Med Rehabil 1990; 69: 6-10.
12. Boutron I, Tubach F, Giraudeau B, Ravaud P. Methodological differences in clinical trials evaluating nonpharmacological and pharmacological treatments of hip and knee osteoarthritis. JAMA 2003; 290: 1062-1070.
13. Jacquier I, Boutron I, Moher D, Roy C, Ravaud P. The reporting of randomized clinical trials using a surgical intervention is in need of immediate improvement: A systematic review. Ann Surg 2006; 244: 677-683.
14. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: Explanation and elaboration. Ann Intern Med 2008; 148: 295-309.
15. Gotzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials 1989; 10: 31-56.
16. Cheng K, Smyth RL, Motley J, O'Hea U, Ashby D. Randomized controlled trials in cystic fibrosis (1966-1997) categorized by time, design, and intervention. Pediatr Pulmonol 2000; 29: 1-7.
17. Devereaux PJ, Bhandari M, Montori VM, Manns BJ, Ghali WA, Guyatt GH. Double blind, you are the weakest link - good-bye! ACP J Club 2002; 136: A11.
18. Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA, Guyatt GH. In the dark: The reporting of blinding status in randomized controlled trials. J Clin Epidemiol 2002; 55: 787-790.
19. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005; 365: 1159-1162.
20. Haahr MT, Hrobjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. Clin Trials 2006; 3: 360-365.
21. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 2001; 285: 2000-2003.
22. Frontera WR, Grimby G, Basford J, Muller D, Ring H. Publishing in physical and rehabilitation medicine. Am J Phys Med Rehabil 2008; 87: 215-220.
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009; 151: 264-269, W64.
24. Abdul Latif L, Daud Amadera JE, Pimentel D, Pimentel T, Fregni F. Sample size calculation in physical medicine and rehabilitation: A systematic review of reporting, characteristics, and results in randomized controlled trials. Arch Phys Med Rehabil 2011; 92: 306-315.
25. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA 2002; 287: 2973-2982.
26. Schulz KF, Grimes DA. Blinding in randomised trials: Hiding who got what. Lancet 2002; 359: 696-700.
27. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: A comparative before-andafter evaluation. JAMA 2001; 285: 1992-1995.
28. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust 2006; 185: 263-267.
29. Piggott M, McGee H, Feuer D. Has CONSORT improved the reporting of randomized controlled trials in the palliative care literature? A systematic review. Palliat Med 2004; 18: 32-38.
30. Ivers NM, Taljaard M, Dixon S, Bennett C, McRae A, Taleban J, et al. Impact of CONSORT extension for cluster randomised trials on quality of reporting and study methodology: Review of random sample of 300 trials, 2000-2008. BMJ 2011; 343: D5886.
31. Meinert CL, Tonascia S, Higgins K. Content of reports on clinical trials: A critical review. Control Clin Trials 1984; 5: 328-347.
32. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Methods and processes of the CONSORT Group: Example of an extension for trials assessing nonpharmacologic treatments. Ann Intern Med 2008; 148: W60-W60.
33. Stein J, Hughes R, D'Andrea S, Therrien B, Niemi J, Krebs K, et al. Stochastic resonance stimulation for upper limb rehabilitation poststroke. Am J Phys Med Rehabil 2010; 89: 697-705.
34. Boutron I, Guittet L, Estellat C, Moher D, Hrobjartsson A, Ravaud P.Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. PLoS Med 2007; 4: E61.
35. Lowe CJ, Wilson MS, Sackley CM, Barker KL. Blind outcome assessment: The development and use of procedures to maintain and describe blinding in a pragmatic physiotherapy rehabilitation trial. Clin Rehabil 2011; 25: 264-674.
36. Falconer J, Hayes KW, Chang RW. Therapeutic ultrasound in the treatment of musculoskeletal conditions. Arthritis Care Res 1990; 3: 85-91.
37. Schulz KF, Altman DG, Moher D, Fergusson D. CONSORT 2010 changes and testing blindness in RCTs. Lancet 2010; 375: 1144-1146.